# Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation

> **NCT04698850** · PHASE4 · WITHDRAWN · sponsor: **Faculty Hospital Kralovske Vinohrady**

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Aflibercept 40 MG/ML [Eylea]
- **DRUG:** Brolucizumab-Dbll 120 MG/ML [Beovu]
- **DRUG:** Ranibizumab 6 MG/ML [Lucentis]

## Key facts

- **NCT ID:** NCT04698850
- **Lead sponsor:** Faculty Hospital Kralovske Vinohrady
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-04
- **Primary completion:** 2023-01
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding issues
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04698850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04698850, "Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04698850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*